Orally administered IFN-α acts alone and in synergistic combination with intraperitoneally administered IFN-γ to exert an antitumor effect against B16 melanoma in mice

Journal of Interferon and Cytokine Research

Volumn 18, Issue 1, 1998, Pages 17-20

  Fleischmann Jr , W Robert ^a   Masoor, Jyoti ^a   Wu, Tzu Y ^a   Fleischmann, Christina M ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RECOMBINANT GAMMA INTERFERON;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; INTRAPERITONEAL DRUG ADMINISTRATION; LIFESPAN; MELANOMA; MOLECULAR INTERACTION; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANIMALIA;

EID: 0031905783     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1998.18.17     Document Type: Article

References (26)

1. BARON, S., COPPENHAVER, D.H., DIANZANI, F., FLEISCHMANN, W.R., Jr., HUGHES, T.K., NIESEL, D.W., STANTON, G.J., and TYRING, S.K. (1992). Introduction to the interferon system. In: Interferon: Principles and Medical Applications. S. Baron, D.H. Coppenhaver, F. Dianzani, W.R. Fleischmann, Jr., T.K. Hughes, D.W. Niesel, G.J. Stanton, and S.K. Tyring (eds.). Galveston: University of Texas Medical Branch at Galveston Press, pp. 1-15.
2. TYRING, S.K. (1992). Introduction to clinical uses of interferons. In: Interferon: Principles and Medical Applications. S. Baron, D.H. Coppenhaver, F. Dianzani, W.R. Fleischmann, Jr., T.K. Hughes, D.W. Niesel, G.J. Stanton, and S.K. Tyring (eds.). Galveston: University of Texas Medical Branch at Galveston Press, pp. 399-408.
3. HUTCHINSON, V., and CUMMINS, J.M. (1987). Low-dose oral interferon in patient with AIDS. Lancet 2, 1530-1531.
4. CUMMINS, J.M., TOMPKINS, M.B., OLSEN, R.G., TOMPKINS, W.A., and LEWIS, M.G. (1988). Oral use of human alpha interferon in cats. J. Biol. Response Mod. 7, 513-523.
5. KOECH, D.K., OBEL, A.O., MINOWADA, J., HUTCHINSON, V.A., and CUMMINS, J.M. (1990). Low dose oral alpha-interferon therapy for patients seropositive for the human immunodeficiency virus type-1 (HIV-1). Mol. Biother. 2, 91-95.
6. ZIELINSKA, W., PASZKIEWICZ, J., KORCZAK, A., WLASIUK, M., ZOLTOWSKA, A., SZUTOMCZ, A., CUMMINS, J.M., and GEORGIADES, J.A. (1993). Treatment of six patients with chronic active HCV hepatitis with low dose natural human interferon alpha administered orally. Arch. Immunol. Ther. Exp. 41, 253-257.
7. JORDAN, W.C. (1994). Three open-label studies of oral interferon alpha in the treatment of HIV disease. J. Natl. Med. Assoc. 86, 257-262.
8. CUMMINS, J.M., MOCK, R.E., SHIVE, B.W., KRAKOWKA, S., RICHARDS, A.B., and HUTCHESON, D.P. (1995). Oral treatment of transmissible gastroenteritis with natural human interferon alpha: a field study. Vet. Immunol. Immunopathol. 45, 355-360.
9. GEORGIADES, J.A. (1996). Natural human interferon alpha may act differently when given parenterally or orally to patients chronically infected with hepatitis B virus. Arch. Immunol. Ther. Exp. 44, 11-22.
10. FLEISCHMANN, W.R., Jr., FIELDS, E.E., WANG, J.L., HUGHES, T.K., and STANTON, G.J. (1991). Modulation of peripheral leukocyte counts in mice by oral administration of interferons. Proc. Soc. Exp. Biol. Med. 197, 424-430.
11. KOREN, S., and FLEISCHMANN, W.R., Jr. (1993). Orally administered interferons suppress bone marrow function. Proc. Soc. Exp. Biol. Med. 204, 155-164.
12. BROD, S.A., and BURNS, D.K. (1994). Suppression of relapsing experimental autoimmune encephalomyelitis in the SJL/J mouse by oral administration of type I interferons. Neurology 44, 1144-1148.
13. BROD, S.A., and KHAN, M. (1996). Oral administration of IFN-alpha is superior to subcutaneous administration of IFN-alpha in the suppresson of chronic relapsing experimental autoimmune encephalomyelitis. J. Autoimmunol. 9, 11-20.
14. MOORE, B.R., KRAKOWA, S., CUMMINS, J.M., and ROBERTSON, J.T. (1996). Changes in airway inflammatory cell populations in standard bred racehorses after interferon-alpha administration. Vet. Immunol. Immunopathol. 49, 347-358.
15. BROD, S.A., KERMAN, R.H., NELSON, L.D., MARSHALL, G.D., Jr., HENNINGER, E.M., KHAN, M., JIN, R., and WOLINSKY, J.S. (1997). Ingested IFN-α has biological effects in humans with relapsing-remitting multiple sclerosis. Mult. Sclerosis 3, 1-7.
16. DEGRE, M., and BUKHOLM, G. (1995). Orally administered interferon-gamma but not tumor necrosis factor-alpha suppress infection with Salmonella typhimurium in a mouse model. J. Biol. Reg. Homeost. Agents 9, 15-20.
17. KAIDO, T.J. (1997). Intranasal administration of IFN-α/β inhibits the development of visceral tumor metastases. J. Interferon Cytokine Res. 17, 31-36.
18. KRAMER, M.J., DENNIN, R., KRAMER, C., JONES, G., CONNELL, E., ROLON, N., GRUARIN, A., KALE, R., and TROWN, P.W. (1983). Cell and virus sensitivity studies with recombinant human alpha interferons. J. Interferon Res. 3, 425-435.
19. ROSENTHAL, G.J., STRANAHAN, R.P., III, THOMPSON, M., BLAIR, P., GERMOLEC, D.R., COMMENT, C.E., SCHWAB, K., and LUSTER, M.I. (1990). Organ-specific hematopoietic changes induced by a recombinant human interferon-alpha in mice. Fundam. Appl. Toxicol. 14, 666-675.
20. FIDLER, I.J. (1973). Selection of successive tumor lines for metastasis. Nature 242, 148-149.
21. KOREN, S., WHORTON, E.B., Jr., and FLEISCHMANN, W.R., Jr. (1993). Circadian dependence of interferon antitumor activity in mice. J. Natl. Cancer Inst. 85, 1927-1932.
22. NOVAKOVIC, S., and FLEISCHMANN, W.R., Jr. (1993). Antitumor effect of interferon-α administered by different routes of treatment. Radiol. Oncol. 27, 286-292.
23. SPECTOR, S.A., TYNDALL, M., and KELLY, E. (1982). Effects of acyclovir combined with other antiviral agents on human cytomegalovirus. Am. J. Med. 73, 36-39.
24. FLEISCHMANN, W.R., Jr., GEORGIADES, J.A., OSBORNE, L.C., and JOHNSON, H.M. (1979). Potentiation of interferon activity by mixed preparations of fibroblast and immune interferon. Infect. Immun. 26, 248-253.
25. FLEISCHMANN, W.R., Jr., SCHWARZ, L.A., and FLEISCHMANN, C.M. (1984). Requirement for IFN-gamma in potentiation of interferon's antiviral and anticellular activities: identity of mouse and human systems. J. Interferon Res. 4, 265-274.
26. FLEISCHMANN, W.R., Jr., KOREN, S., and FLEISCHMANN, C.M. (1992). Orally administered interferons exert their WBC suppressive effects via a novel mechanism. Proc. Soc. Exp. Biol. Med. 201, 200-207.